

References

- ACOG. Uterine fibroids. July 2022. Accessed September 1, 2022. <https://www.acog.org/womens-health/faqs/uterine-fibroids>
- ACOG Committee Opinion No. 760: dysmenorrhea and endometriosis in the adolescent. *Obstet Gynecol*. 2018;132(6):e249-e258.
- Aninye IO, Laitner MH, Society for Women's Health Research Uterine Fibroids Working Group. Uterine fibroids: assessing unmet needs from bench to bedside. *J Womens Health (Larchmt)*. 2021;30(8):1060-1067.
- Baird DD, Patchel SA, Saldana TM, et al. Uterine fibroid incidence and growth in an ultrasound-based, prospective study of young African Americans. *Am J Obstet Gynecol*. 2020;223(3):402.e1-402.e18.
- Becker CM, Bokor A, Heikinheimo O, et al; ESHRE Endometriosis Guideline Group. ESHRE guideline: endometriosis. *Hum Reprod Open*. 2022;2022(2):hoac009.
- Carvalho N, Margatho D, Cursino K, Benetti-Pinto CL, Bahamondes L. Control of endometriosis-associated pain with etonogestrel-releasing contraceptive implant and 52-mg levonorgestrel-releasing intrauterine system: randomized clinical trial. *Fertil Steril*. 2018;110(6):1129-1136.
- Falcone T, Flyckt R. Clinical management of endometriosis. *Obstet Gynecol*. 2018;131(3):557-571.
- Giudice LC, As-Sanie S, Arjona Ferreira JC, et al. Once daily oral relugolix combination therapy versus placebo in patients with endometriosis-associated pain: two replicate phase 3, randomised, double-blind, studies (SPIRIT 1 and 2). *Lancet*. 2022;399(10343):2267-2279.
- Hodgson R, Chittawar PB, Farquhar C. GnRH agonists for uterine fibroids. *Cochrane Database Syst Rev*. 2017;2017(1):CD012846.
- Laughlin-Tommaso SK, Khan Z, Weaver AL, Smith CY, Rocca WA, Stewart EA. Cardiovascular and metabolic morbidity after hysterectomy with ovarian conservation: a cohort study. *Menopause*. 2018;25(5):483-492.
- Lupron depot [package insert]. Chicago, IL: AbbVie Inc.; 2022.
- Marsh EE, Al-Hendy A, Kappus D, Galitsky A, Stewart EA, Kerolous M. Burden, prevalence, and treatment of uterine fibroids: a survey of U.S. women. *J Womens Health*. 2018;27(11):1359-1367.
- Myfembree [package insert]. Brisbane, CA: Myovant Sciences, Inc.; 2022.
- ObsEva SA. ObsEva announces final results from the phase 3 PRIMROSE program of Yseltly® (linzagolix) for the treatment of uterine fibroids. May 20, 2021. Accessed January 23, 2022. <https://www.globenewswire.com/en/news-release/2021/05/20/2232978/0/en/ObsEva-Announces-Final-Results-from-the-Phase-3-PRIMROSE-Program-of-Yseltly-linzagolix-for-the-Treatment-of-Uterine-Fibroids.html>
- Oriahnn [package insert]. Chicago, IL: AbbVie Inc.; 2021.
- Peitsidis P, Koukoulomati A. Tranexamic acid for the management of uterine fibroid tumors: a systematic review of the current evidence. *World J Clin Cases*. 2014;2(12):893-898.
- Zakhari A, Delpero E, McKeown S, Tomlinson G, Bougie O, Murji A. Endometriosis recurrence following post-operative hormonal suppression: a systematic review and meta-analysis. *Hum Reprod Update*. 2021;27(1):96-107.